SynthesisMedicine2025
The efficacy of Shenyankangfu tablets in combination with valsartan in diabetic nephropathy: A systematic review and meta-analysis.
Synthesis in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimal drug treatment for children with IgA vasculitis nephritis: a systematic review and network meta-analysis.Translational pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is the most prevalent and critical microvascular complication of diabetes mellitus, constituting a significant contributor to end-stage renal disease. Shenyankangfu tablets (SYKFP) are a pure traditional Chinese medicine compound. Current studies have shown that SYKFP combined with valsartan in the treatment of DN had therapeutic advantages. However, there is still a lack of systematic research. Therefore, meta-analysis was used to systematically evaluate the efficacy and safety of SYKFP combined with valsartan in treating DN and to provide evidence-based medical evidence for clinical application.
methodsCNKI, VIP, Wanfang, Chinese Biomedical Literature Service System, American Clinical Trial Registry, Embase, Web of Science, PubMed, and Cochrane Library databases were searched from the date of database establishment to August 2024. All randomized controlled trials of SYKFP in combination with valsartan for treating DN were collected, and the data of clinical trials that met the inclusion criteria were extracted. Meta-analysis was performed using Review Manager 5.4 and Stata 17.0.
resultsSixty-nine pieces of literature were retrieved, and 14 eligible randomized controlled trials were selected, with 1281 participants. The results of the meta-analysis showed that compared with valsartan alone in the treatment of DN, Shenyanangfu tablets combined with valsartan can improve the clinical efficacy rate (relative risk = 1.16, 95% CI [1.11, 1.22], P < .00001) and reduce blood creatinine (mean difference [MD] = -28.79, 95% CI [-31.16, -26.42], P < .00001), urea nitrogen (MD = -1.37, 95% CI [-1.52, -1.22], P < .00001), 24-hour urine protein quantification (MD = -0.59, 95% CI [-0.77, -0.40], P < .00001), fasting blood glucose (MD = -0.51, 95% CI [-0.77, -0.25], P = .0001) and the incidence of adverse events (relative risk = 0.74, 95% CI [0.43, 1.23], P = .24) were better than valsartan alone, and the difference was statistically significant.
conclusionSYKFP combined with valsartan can improve the clinical treatment efficiency of DN. They can effectively reduce the occurrence of urea nitrogen, blood creatinine, 24-hour urine protein quantification, fasting blood glucose, and adverse events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.